Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02892149




Registration number
NCT02892149
Ethics application status
Date submitted
2/09/2016
Date registered
8/09/2016
Date last updated
28/06/2022

Titles & IDs
Public title
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Scientific title
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE-CONVERSION)
Secondary ID [1] 0 0
2016-001360-11
Secondary ID [2] 0 0
AKB-6548-CI-0017
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anemia 0 0
Dialysis-Dependent Chronic Kidney Disease 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vadadustat
Treatment: Drugs - Darbepoetin alfa

Experimental: Vadadustat -

Active comparator: Darbepoetin alfa -


Treatment: Drugs: Vadadustat
Oral dose administered once daily for =36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Treatment: Drugs: Darbepoetin alfa
Subcutaneous or intravenous dose administered for =36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)
Timepoint [1] 0 0
Baseline; Weeks 24 to 36
Primary outcome [2] 0 0
Median Time to First Major Adverse Cardiovascular Event (MACE)
Timepoint [2] 0 0
Up to 170 weeks
Secondary outcome [1] 0 0
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)
Timepoint [1] 0 0
Baseline; Weeks 40 to 52
Secondary outcome [2] 0 0
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis
Timepoint [2] 0 0
Up to 170 weeks
Secondary outcome [3] 0 0
Median Time to First Cardiovascular MACE
Timepoint [3] 0 0
Up to 170 weeks
Secondary outcome [4] 0 0
Median Time to First Cardiovascular Death
Timepoint [4] 0 0
Up to 170 weeks
Secondary outcome [5] 0 0
Median Time to First All-cause Mortality
Timepoint [5] 0 0
Up to 170 weeks

Eligibility
Key inclusion criteria
* =18 years of age
* Receiving chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease for at least 12 weeks prior to Screening
* Currently maintained on erythropoiesis-stimulating agent therapy, with a dose received within 6 weeks prior to or during Screening
* Mean Screening hemoglobin between 8.0 and 11.0 grams per deciliter (g/dL) (inclusive) in the US and between 9.0 and 12.0 g/dL (inclusive) outside of the US
* Serum ferritin =100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) =20% during Screening
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Anemia due to a cause other than chronic kidney disease or participants with active bleeding or recent blood loss
* Uncontrolled hypertension
* Red blood cell transfusion within 8 weeks prior to randomization
* Anticipated to recover adequate kidney function to no longer require dialysis
* Severe heart failure at Screening (New York Heart Association Class IV)
* Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure, or stroke within 12 weeks prior to or during Screening
* Hypersensitivity to Vadadustat, Darbepoetin alfa, or any of their excipients

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/03/2020
Sample size
Target
Accrual to date
Final
3554
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC,WA
Recruitment hospital [1] 0 0
Research Site - Liverpool
Recruitment hospital [2] 0 0
Research Site - New Lambton Heights
Recruitment hospital [3] 0 0
Research Site - Wahroonga
Recruitment hospital [4] 0 0
Research Site - Cairns
Recruitment hospital [5] 0 0
Research Site - Launceston
Recruitment hospital [6] 0 0
Research Site - Box Hill
Recruitment hospital [7] 0 0
Research Site - Fitzroy
Recruitment hospital [8] 0 0
Research Site - Nedlands
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
2076 - Wahroonga
Recruitment postcode(s) [4] 0 0
4870 - Cairns
Recruitment postcode(s) [5] 0 0
7250 - Launceston
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment postcode(s) [7] 0 0
3065 - Fitzroy
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Rhode Island
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Vermont
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Cordoba
Country [29] 0 0
Argentina
State/province [29] 0 0
Corrientes
Country [30] 0 0
Argentina
State/province [30] 0 0
Salta
Country [31] 0 0
Argentina
State/province [31] 0 0
San Luis
Country [32] 0 0
Brazil
State/province [32] 0 0
Bahia
Country [33] 0 0
Brazil
State/province [33] 0 0
Ceará
Country [34] 0 0
Brazil
State/province [34] 0 0
Espírito Santo
Country [35] 0 0
Brazil
State/province [35] 0 0
Minas Gerais
Country [36] 0 0
Brazil
State/province [36] 0 0
Paraná
Country [37] 0 0
Brazil
State/province [37] 0 0
Rio Grande Do Sul
Country [38] 0 0
Brazil
State/province [38] 0 0
Santa Catarina
Country [39] 0 0
Brazil
State/province [39] 0 0
Sao Paulo
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Byala
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Cherven bryag
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Dobrich
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Dupnitsa
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Haskovo
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Plovdiv
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Ruse
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Shumen
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Silistra
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Sliven
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Sofia
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Varna
Country [52] 0 0
Bulgaria
State/province [52] 0 0
Veliko Tarnovo
Country [53] 0 0
Bulgaria
State/province [53] 0 0
Vidin
Country [54] 0 0
Bulgaria
State/province [54] 0 0
Vratsa
Country [55] 0 0
Canada
State/province [55] 0 0
Nova Scotia
Country [56] 0 0
Canada
State/province [56] 0 0
Ontario
Country [57] 0 0
Canada
State/province [57] 0 0
Quebec
Country [58] 0 0
France
State/province [58] 0 0
Bouches-du-Rhône
Country [59] 0 0
France
State/province [59] 0 0
Gironde
Country [60] 0 0
France
State/province [60] 0 0
Loire
Country [61] 0 0
France
State/province [61] 0 0
Marne
Country [62] 0 0
France
State/province [62] 0 0
Paris
Country [63] 0 0
Germany
State/province [63] 0 0
Baden Wuerttemberg
Country [64] 0 0
Germany
State/province [64] 0 0
Mecklenburg Vorpommern
Country [65] 0 0
Germany
State/province [65] 0 0
Nordrhein Westfalen
Country [66] 0 0
Germany
State/province [66] 0 0
Berlin
Country [67] 0 0
Israel
State/province [67] 0 0
Ashkelon
Country [68] 0 0
Israel
State/province [68] 0 0
Haifa
Country [69] 0 0
Israel
State/province [69] 0 0
Jerusalem
Country [70] 0 0
Israel
State/province [70] 0 0
Kfar- Saba
Country [71] 0 0
Israel
State/province [71] 0 0
Rishon Lezion
Country [72] 0 0
Italy
State/province [72] 0 0
Bari
Country [73] 0 0
Italy
State/province [73] 0 0
Genova
Country [74] 0 0
Italy
State/province [74] 0 0
Lecco
Country [75] 0 0
Italy
State/province [75] 0 0
Pavia
Country [76] 0 0
Italy
State/province [76] 0 0
Roma
Country [77] 0 0
Italy
State/province [77] 0 0
Siena
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Gangwon-do
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Gyeonggi-do
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Busan
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Seoul
Country [82] 0 0
Mexico
State/province [82] 0 0
Hidalgo
Country [83] 0 0
Mexico
State/province [83] 0 0
Jalisco
Country [84] 0 0
Mexico
State/province [84] 0 0
Michoacán
Country [85] 0 0
Mexico
State/province [85] 0 0
Sinaloa
Country [86] 0 0
Poland
State/province [86] 0 0
Biala Podlaska
Country [87] 0 0
Poland
State/province [87] 0 0
Golub Dobrzyn
Country [88] 0 0
Poland
State/province [88] 0 0
Kolobrzeg
Country [89] 0 0
Poland
State/province [89] 0 0
Lodz
Country [90] 0 0
Poland
State/province [90] 0 0
Warszawa
Country [91] 0 0
Portugal
State/province [91] 0 0
Beja
Country [92] 0 0
Portugal
State/province [92] 0 0
Leiria
Country [93] 0 0
Portugal
State/province [93] 0 0
Loures
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Ekaterinburg
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Kemerovo
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Moscow
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Nizhniy Novgorod
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Novorossiysk
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Saint-Petersburg
Country [100] 0 0
Russian Federation
State/province [100] 0 0
St. Petersburg
Country [101] 0 0
Serbia
State/province [101] 0 0
Belgrade
Country [102] 0 0
Serbia
State/province [102] 0 0
Kragujevac
Country [103] 0 0
Serbia
State/province [103] 0 0
Nis
Country [104] 0 0
Serbia
State/province [104] 0 0
Zajecar
Country [105] 0 0
Ukraine
State/province [105] 0 0
Brovary
Country [106] 0 0
Ukraine
State/province [106] 0 0
Cherkassy
Country [107] 0 0
Ukraine
State/province [107] 0 0
Dnipro
Country [108] 0 0
Ukraine
State/province [108] 0 0
Ivano-Frankivsk
Country [109] 0 0
Ukraine
State/province [109] 0 0
Kharkiv
Country [110] 0 0
Ukraine
State/province [110] 0 0
Kyiv
Country [111] 0 0
Ukraine
State/province [111] 0 0
Mykolaiv
Country [112] 0 0
Ukraine
State/province [112] 0 0
Ternopil
Country [113] 0 0
Ukraine
State/province [113] 0 0
Uzhgorod
Country [114] 0 0
Ukraine
State/province [114] 0 0
Vinnytsia
Country [115] 0 0
Ukraine
State/province [115] 0 0
Zaporizhzhia
Country [116] 0 0
Ukraine
State/province [116] 0 0
Zhytomyr
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Cambridgeshire
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Greater London
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Hertfordshire
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Leicestershire
Country [121] 0 0
United Kingdom
State/province [121] 0 0
South Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Akebia Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD)
Trial website
https://clinicaltrials.gov/study/NCT02892149
Trial related presentations / publications
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, Khawaja Z, Koury MJ, Maroni BJ, Matsushita K, McCullough PA, Lewis EF, Luo W, Parfrey PS, Pergola P, Sarnak MJ, Spinowitz B, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Zwiech R, Chertow GM. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956.
Public notes

Contacts
Principal investigator
Name 0 0
Chief Medical Officer
Address 0 0
Akebia Therapeutics Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02892149